Jpmorgan Chase & CO Scynexis Inc Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.93 - $3.64 $91,798 - $173,132	47,564 New	47,564 $108,000
Q1 2023 May 11, 2023	BUY	$1.15 - $3.0 $2,019 - $5,268	1,756 New	1,756 $5,000
Q2 2022 Aug 11, 2022	SELL	$1.77 - $3.87 $7,572 - $16,555	-4,278 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$3.56 - $6.66 $15,229 - $28,491	4,278 New	4,278 $17,000

13.7M

21.9K

2.6K

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $33M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.